Northeast Pharmaceutical Group (SHE:000597) received approval to market raw drug material Efavirenz from the Chinese drug administration, according to a Shenzhen Stock Exchange disclosure on Saturday.
The approval is valid until Feb. 11, 2030.
Efavirenzis a key drug ingredient for the treatment of human immunodeficiency virus infection and a selective non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), the pharmaceutical company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。